Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

REINACH, Switzerland, January 22 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) announced today that patient screening for enrolment into the pivotal Phase III study with the TLT treatment in onychomycosis has been initiated and is progressing at a very good rate.

Approximately 220 patients in total will be enrolled in this study. A substantial number of patients had already expressed their interest to participate well in advance of the trial.

The open label Phase III study will evaluate the efficacy, safety and tolerability of the TLT therapy in the treatment of patients with mild-to-moderate toenail onychomycosis. The TLT therapy consists of a one-time laser pre-treatment, followed by daily application of a topical terbinafine (the active substance of Lamisil(R)) formulation. The comparator is 8% ciclopirox lacquer (Penlac(R)) applied daily to nails that have not undergone a prior laser pre-treatment. The treatment duration will be 48 weeks in both arms.

The primary efficacy endpoint is complete cure, which is defined as 100% clear nails, negative fungal culture results and negative KOH microscopy. Arpida aims to demonstrate superiority of the TLT therapy over the comparator. Secondary endpoints include time to complete cure as well as safety and tolerability of the TLT treatment.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "We are very pleased with the high level of interest displayed by patients for enrolment in this study and we expect a rapid progression of the TLT treatment along its development path. The TLT therapy as a targeted approach could offer significant advantages by providing effective treatment while at the same time avoiding systemic exposure and bypassing the potential side effects of oral therapies. We are on track to complete this trial by early 2009."

About onychomycosis

Onychomycosis (OM) is a fungal infection affecting mainly toenails and, to a lesser extent fingernails
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , NANJING, China, Dec. 2 /PRNewswire-As...the "Company") (NYSE: SCR ), a leading pharmaceu...ufacturing, and marketing of branded,generic and p...ed that 105 of,its drugs have been included in Chi...ich was issued by China,s Ministry of Human Resour...
(Date:12/2/2009)... , SHANGHAI, Dec. 2 /PRNewswire-Asia/ --...arkets are in turmoil and uncertainty is part of m...he pharma industry has been,relatively immune to t... a,vacation. , During the midst of the di...Johnson & Johnson inaugurated an R&D cente...
(Date:12/2/2009)... , HOBOKEN, N.J., Dec. 2 Accor...nt to 45 percent of Americans diagnosed with diabe...y. Diabetic retinopathy, damage to the retina cau...indness in people with diabetes and is one of the ...o 80 percent of all patients who,ve had diabetes f...
(Date:12/1/2009)..., INCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-Fir...I ) today announced revenue guidance for the fourt... $57 million, as compared with $69 million for the...r 2008 results was the first of two installment pa...ed in fourth quarter 2008 results was a one-time $...
Breaking Biology Technology:Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...r Enabling Faster, Easier,Quantification of Protei...e Clinical Trials, WAL...),a leading developer of protein biomarker analysi...ent, today announced the company,s,PATH(R) technol...7 by the,U.S. Patent and Trademark Office. The pat...
...D), an industry-leading provider of Computer-Aided...ation of cancer, today announced that two,U.S. Pat...ly been granted,to the Company by the United State...nts demonstrate our on-going commitment to broaden...represent an important,addition to our portfolio o...
...osclerosis enters the clinic ...ewswire-FirstCall/ - Resverlogix Corp.,("Resverlog...d approval by,the US Food and Drug Administration ...l RVX-208 in the USA. RVX-208 is a novel first-in-... of ApoA-I and HDL. ApoA-I is,regarded as the crit...
Other Biology Technology:Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 2iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology 3FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208 2FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208 3
(Date:12/2/2009)...cientist from the University of Salamanca and anot...nce of predators affects the behaviour of Acantho... Negev Desert in the Near East. According to the s...le and different prey if they are under pressure f...dicted this result, but until now there had been v...
(Date:12/1/2009)...ber 1, 2009: OptiNose is pleased to announce the p...tudy investigating the efficacy and tolerability o...e topical treatment of chronic rhinosinusitis with... of the International and European Rhinologic Soci...ps is a chronic disease that can significantly red...
(Date:12/1/2009)... Georgia Institute of Technology has been awarded ...nostructures for energy harvesting and adaptive ma... cognitive processes of the modern warfighter. ,...enabled Inorganic/Organic Nanostructures and Impro...dimir Tsukruk and Kenneth Sandhage, professors in ...
Breaking Biology News(10 mins):Lizards change their diet to avoid predators 2New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Air Force Center of Excellence awarded in nanostructures and improved cognition 2Air Force Center of Excellence awarded in nanostructures and improved cognition 3Air Force Center of Excellence awarded in nanostructures and improved cognition 4BRIT1 allows DNA repair teams access to damaged sites 49483 1BRIT1 allows DNA repair teams access to damaged sites 49483 2Dysport Available 21 New Wrinkle Treatment in Washington DC Offers Botox Alternative 49480 1Dysport Available 21 New Wrinkle Treatment in Washington DC Offers Botox Alternative 49480 2Highmark Program Receives Top Community Leadership Award 49477 1Highmark Program Receives Top Community Leadership Award 49477 2
...Foundation has announced the award of $263,274 to ...upport her work in exploring the structure, functi...n one of the most important marine primary produce...thetic Response to Abiotic Stress in Prochlorococc...t addresses the remarkable differences in genomes ...
...is working to develop a quick, simple and cheap im...d. It could help HIV/AIDS sufferers in the poorest...ir lives, possibly by as much as 10 to 15 years. ,... consortium, called the CD4 Initiative, led by Imp... Melinda Gates Foundation. Antje J. Baeumner, Corn...
...hing for new methods and therapies to reduce infar... in patients who experience myocardial infarction ...day at the American College of Cardiology’s Innova...., a team from the Duke Clinical Research Institut...ating a novel protein kinase C inhibitor that had ...
Other Biology News:Williams College biologist explores photosynthetic apparatus 2Cornell researcher helping develop quick, cheap HIV/AIDS test 2Protein therapy may reduce infarct size in heart attack patients 2
Lambda Control Kit from ABgene
...olymerase. It is a 5'-exo-minus N-terminally trunc...rom a gene construct in E. coli, translation initi...main of the DNA polymerase-encoding gene. The enzy...le DNA polymerase activity in comparison with Taq ...
Rabbit Anti-Human XM_941015 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
96 Well Base Plate from ABgene
Biology Products: